|
1. Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes
M, Eshleman S, and others. Lifetime and 12-month prevalence of DSM-III-R
psychiatric disorders in the United States: Results from the National
Comorbidity Study. Arch Gen Psychiatry 1994;51:8–19.
2. Tohen M, Angst J. Epidemiology of bipolar disorder.
In: Tsuang MT, Tohen M, editors. Textbook in psychiatric epidemiology.
2nd ed. New York: John Wiley and Sons; 2002. Forthcoming.
3. Goodwin FK, Jamison KR. Manic-depressive illness.
New York: Oxford University Press; 1990.
4. Coryell WS, Scheftner W, Keller M, Endicott J, Maser
J, Klerman GL. The enduring psychosocial consequences of mania and
depression. Am J Psychiatry 1993;150:720–7.
5. Dion GL, Tohen M, Anthony WA, Waternaux CS. Symptoms
and functioning of patients with six months after hospitalization.
Hospital and Community Psychiatry 1988;39:652–7.
6. Gitlin MJ, Swendsen J, Heller TL, Hammen C. Relapse
and impairment in bipolar disorder. Am J Psychiatry 1995;152:1635–40.
7. Tohen M, Hennen J, Zarate CA Jr, Baldessarinin RJ,
Strakowski SM, Stoll AL, and others. The McLean first episode project:
two0year syndromal and functional recovery in 219 cases of major
affective disorders with psychotic features. Am J Psychiatry 2000;157:220–8.
8. Tondo L, isaacsson G, Baldessarinin RJ. Suicide
in bipolar disorder. Risk and prevention. CNS Drugs 2002. Forthcoming.
9. Aksiskal HS, Bourgeois ML, Angst J, Post R, Moller
H, Hirschfield R. Re-evaluating the prevalence of and diagnostic
composition within the broad clinical spectrum of bipolar disorders.
J Affect Disord 2000;59 (Suppl 1):5–30.
10. Leibenluft E. Women with bipolar illness: clinical
and research issues. Am J Psychiatry 1996;153:163–73.
11. Cohen LS, Friedman JM, Jefferson JW, Johnson EM,
Weiner ML. A reevaluation of risk of in utero exposure to lithium.
JAMA 1994;271:146–50.
12. Bouffard S, Viguera AC, Cohen LS. Bipolar women
and pregnancy. Weighing the risks following antenatal consultation.
New Investigator poster session. American Psychiatric Association;
2001; New Orelans (LA).
13. Kendell RE, Chalmers JC, Platz C. Epidemiology
of puerperal psychoses. Br J Psychiatry 1987;150:662–73.
14. Lier L, Kastrup M, Rafaelsen O. Psychiatric illness
in relation to pregnancy and childbirth: diagnostic profiles, psychosocial
and perinatal aspects. Nordisk Psykiatrisk Tidsskrift 1989;43:535–42.
15. Marce L. Traite de la folie des femmes enceintes,
des nouvelles accouchees et des nourrices. Paris: JB Bailliere et
Fils; 1858.
16. Kraepelin E. Manic-depressive insanity and paranoia.
Barclay RM, translator; Robertson GM, editor. Edinburgh: E and S
Livingstone; 1921. Translation of: Psychiatrie: Ein Kurzes Lehrbuch
für Studirende und Ärtze. 8th ed.
17. Targum SD, Davenport YB, Webster MJ. Postpartum
mania in bipolar manic depressive patients withdrawn from lithium
carbonate. J Nerv Ment Dis 1979;167:572–4.
18. McNeil T, Kaij L, Malmquist-Larsson A. Women with
nonorganic psychosis: Factors associated with pregnancy’s effect
on mental health. Acta Psychiatr Scand 1984;70; 09–19.
19. Sharma V, Persad P. Effect of pregnancy on three
patients with bipolar disorder. Ann Clin Psychiatry 1995;7:39–42.
20. Marzuk PM, Tardiff K, Leon AC, Hirsch CS, Portera
L, Hartwell N, and others. Lower risk of suicide during pregnancy.
Am J Psychiatry 1997;154:122–3.
21. Pugh TF, Schmidt WM, Reed RB. Rates of mental disease
related to childbearing. N Engl J Med 1963;268.
22. Nott PN. Psychiatric illness following childbirth
in Southhampton: a case register study. Psychol Med 1982;12: 57–61.
23. Terp IM, Mortensen PB. Post-partum psychoses: clinical
diagnoses and relative risk of admission after parturition. Br J
Psychiatry 1998;172:521–6.
24. Grof PR, Robbins W, Alda M, Berghoefer A, Vojtechovsky
M, Nilsson A, and others. Protective effect of pregnancy in women
with lithium-responsive. J Affect Disord 2000;61;31–9.
25. Viguera AC, Cohen LS, Tondo L, Baldessarini RJ.Reply
to P Groff: protective effect of pregnancy in women with lithium-responsive
bipolar disorder [letter]. J Affective Disord 2002; forthcoming.
26.Viguera AC, Nonacs R, Cohen LS, Tondo L, Murray
A, Baldessarini RJ. Risk of recurrence of bipolar disorder in pregnant
and nonpregnant women after discontinuing lithium maintenance. Am
J Psychiatry 2000;157:179–84.
27. Finnerty M, Levin Z, Miller LJ. Acute manic episodes
in pregnancy. Am J Psychiatry 1996;153;261–3.
28. Baldessarini RJ, Tondo L, Viguera AC. Effects of
discontinuing lithium maintenance treatment. Bipolar Disorders 1999;1:17–24.
29. Blehar M, DePaulo J, Gershon E, Reich T, Simpson
S, Nurnberger J. Women with bipolar disorder: findings from the
NIMH genetics initiative sample. Psychopharmacol Bull 1988;34:239–43.
30. Freeman MP, Wosnitzer Smith K, Freeman S, McElroy
SL, Kmetz GF, Wright R, and others. The impact of reproductive events
on the course of bipolar disorder in women. J Clin Psychiatry 2002;63:284–7.
31. Lapierre YD, Gagnon A, Kokkinidis L. Rapid recurrence
of mania following lithium withdrawal. Biol Psychiatry 1980;15:859–64.
32. Suppes T, Baldessarini RJ, Faedda GL, Tohen M:
Risk of recurrence following discontinuation of lithium treatment
in bipolar disorder. Arch Gen Psychiatry 1991;48:1082–8.
33. Faedda GL, Tondo L, Baldessarini RJ, Suppes T,
Tohen M. Outcome after rapid vs gradual discontinuation of lithium
treatment in bipolar mood disorders. Arch Gen Psychiatry 1993;50:448–55.
34. Rosenbaum JF, Sachs GS, Lafer B: High rates of
relapse in bipolar patients abruptly changed from standard to low
serum lithium levels in a double-blind trial. Paper presented at
the American College of Neuropsychopharmacology; 1994; San Juan,
Puerto Rico.
35. Baldessarini RJ, Tondo L, Faedda GL, Floris G,
Suppes T, Rudas N. Effects of rate of discontinuing lithium maintenance
treatment. J Clin Psychiatry 1996;57:441–8.
36. Baldessarini RJ, Tondo L, Floris G. Rudas N. Reduced
morbidity after gradual discontinuation of lithium treatment for
bipolar I and II disorders: replication study. Am J Psychiatry 1997;154:551–3.
37. Braftos OHJ. Puerperal mental disorders in manic
depressive females. Acta Psychiatr Scand 1966;42;285–94.
38. Reich T, Winokur G. Postpartum psychosis in patients
with manic-depressive disease. J Nerv Ment Dis 1970;51:60–8.
39. Brockington IF, Cernik KF, Schofield EM, Downing
AR, Francis AF, Keelan C. Puerperal psychosis: phenomena and diagnosis.
Arch Gen Psychiatry 1981;38:829–33.
40. Davidson J, Robertson E. A follow-up study of postpartum
illness. Acta Psychiatr Scand 1985;71:451–7.
41. Klompenhouwer J, van Hulst A. Classification of
postpartum psychosis: a study of 250 mother and baby admissions
in the Netherlands. Acta Psychiatr Scand 1991;84:255–61.
42. Rhode A, Marneros A. Bipolar disorders during pregnancy,
postpartum, and in menopause. In: Marneros A, Angst J, editors.
Bipolar disorders: 100 years after manic-depressive insanity. London:
Klüwer Academic Publishers; 2000. p 127–37.
43. Stewart DE. Prophylactic lithium in postpartum
affective psychosis. J Nerv Ment Dis 1988;176:485–9.
44. Stewart DE, Klompenhouwer JL, Kendall RE, van Hulst
AM. Prophylatic lithium in puerperal psychosis: experience of three
centers. Br J Psychiatry 1991;158:393–7.
45. Austin MPV. Puerperal affective psychosis: is there
a case for lithium prophylaxis? Br J Psychiatry 1992;161:692–4.
46. Cohen LS. Sichel DA, Robertson LM, Heckscher E,
Rosenbaum JF. Postpartum prophylaxis for women with bipolar disorder.
Am J Psychiatry 1995;152:1641–5.
47. Abou-Saleh MT, Coppen A. Puerperal affective disorders
and response to lithium [Letter]. Br J Psychiatry 1983;142;539.
48. Van Gent EM, Verhoeven WM: Bipolar illness, lithium
prophylaxis, and pregnancy. Pharmacopsychiatry 1992;25:187–91.
49. Wisner K. Prevention of postpartum episodes in
bipolar women [abstract]. In: Syllabus and Proceedings Summary of
the 151st Ann Meeting American Psychiatric Association; May 17-22,
1997; Toronto (ON). Washington (DC): APA. 1998.
50. Altshuler LL, Cohen LS, Szuba MP, Burt VK, Gitlin
M, Mintz J. Pharmacologic management of psychiatric illness in pregnancy:
dilemmas and guidelines. Am J Psychiatry 1996;153:592–606.
51. Cohen LS, Altshuler LL. Pharmacologic management
of psychiatric illness during pregnancy and the postpartum period.
Psychiatr Clin North Am 1997;4:21–60.
52.Cohen LS, Rosenbaum JF. Psychotropic drug use during
pregnancy: weighing the risks. J Clin Psychiatry 1998;59 (Suppl
2):18–28.
53. Briggs GG, Freeman RK, Schofield EM. Drugs in pregnancy
and lactation: a reference guide to fetal and neonatal risk. 5th
ed. Baltimore (MD): William and Wilkins; 1997.
54. Shepard TH, Brent RL, Friedman JM, Jones KL, Miller
RK, Moore CA, and others. Update on new developments in the study
of human teratogens. Teratology 2002;65:153–61.
55. Friedman JM, Polifka JE. Teratogenic effects of
drugs: a resource for clinicians. Baltimore: Johns Hopkins University
Press; 1994.
56. Chambers CD, Johnson KA, Dick LM, Felix RJ, Jones
KL. Birth outcomes in pregnant women taking fluoxetine. New Engl
J Med 1996;335:1010–5.
57. Pastuszak A, Schick-Boschetto B, Zuber C, Feldcamp
M, Pinelli M, Sihn S, and others. Pregnancy outcome following first-trimester
exposure to fluoxetine (Prozac). JAMA 1993;269:2246–8.
58. Teratology Society Public Affairs Committee. FDA
classification of drugs for teratogenic risk. Teratology 1994;49:446–7.
59. Fabro SE. Clinical obstetrics. New York: John Wiley
and Sons; 1987.
60. Langman J. Human development-normal and abnormals.
In: Langman J. Medical embryology. Baltimore (MD): Williams and
Wilkins; 1985.
61. Nora JJ, Nora AH, Toews WH. Lithium, Ebstein’s
anomaly and other congenital heart defects. Lancet 1974;2:594–5.
62. Schou M, Goldfield MD, Weinstein MR, Villeneuve
A. Lithium and pregnancy, I: report from the register of lithium
babies. BMJ 1973:2;135–6.
63. Schou M. Lithium treatment during pregnancy, delivery,
and lactation: an update. J Clin Psychiatry 1990;51:410–13.
64. Weinstein MR. The international register of lithium
babies. Drug Information Journal 1976;50:81–6.
65. Llewellyn A, Stowe Z, Strader JR. The use of lithium
and management of women with bipoalr disorder during pregnancy and
lactation. J Clin Psychiatry 1998;59 (Suppl 6):57–64.
66. Edmonds LD, Oakley GP. Ebstein’s anomaly and
maternal lithium exposure during pregnancy. Teratology 1990;41:551–2.
67. Jacobson SJ, Jones K, Johnson K, Ceolin L, Kaur
P, Sahn D, and others: Prospective multicentre study of pregnancy
outcome after lithium exposure during first trimester. Lancet 1992;339:530–3.
68. Kallen B, Tandberg A. Lithium and the placenta.
Acta Psychiatr Scand 1983;68:134–9.
69. Zalzstein E, Koren G, Einarson T, Freedom RM. A
case control study on the association between first-trimester exposure
to lithium and Ebstein’s anomaly. Am J Cardiol 1990;65:817–8.
70. Yonkers KA, Little BB, March D. Lithium during
pregnancy: drug effects and therapeutic implications. CNS Drugs
1998;4:261–9.
71. Woody JN, London WL, Wilbanks GD Jr: Lithium toxicity
in a newborn. Pediatrics 1971;47:94–6.
72. Ananth J. Side effects on fetus and infant of psychotropic
drug use during pregnancy. International Pharmacopsychiatry 1976;11:246–60.
73. Davis LL, Shannon S, Drake RG, Petty F. The treatment
of bipolar disorder during pregnancy. In: Yonkers K, Little B, editors.
Psychiatric disorders in pregnancy. London: Arnold; 20001. p 122–33.
74. Schou M: What happened later to the lithium babies?
A follow-up study of children born without malformations. Acta Psychiatr
Scand 1976;54:193–7.
75. Viguera AC, McCarthy C, Whitfield TH, Poitra JR,
Bekken K, Sherman J, and others. Neurobehavioral outcome following
lithium exposure: what happens to lithium babies. American Psychiatric
Association; 2001; New Orleans (LA).
76. Yerby MS. Problems and management of the pregnant
woman with epilepsy. Epilepsia 1987;28 (Suppl 3):29–36.
77. Holmes LB, Harvey EA, Coull BA. Huntington KB,
Khoshbin S, Hayes AM, and others. Teratogenicity of anticonvulsant
drugs. N Engl J Med 2002;334:1132–8.
78. Koch S, Losche G, Jager-Roman E, Jacob S, Rating
D,and others: Major and minor birth malformations and antiepileptic
drugs. Neurology 1992;42 (Suppl 5):83–8.
79. Morrell MJ. Pregnancy and epilepsy. In: Porter
RJ, Chadwick D, editors. The epilepsies. Boston: Butterworth-Heinemann;
1997. p 313–32.
80. Orup HI, Holmes LB. Persistence of craniofacial
effect of antiepileptic drug (AED) teratogenicity with adult years.
Teratology 1997;55:34.
81. Samren EB, van Duijn CM, Koch S, Hiilesmaa VK,
Klepel M, Bardy AH, and others. Maternal use of antiepileptic drugs
and risk of major congenital malformations: a joint European prospective
study of human teratogenesis associated with maternal epilepsy.
Epilepsia 1997;38:981–90.
82. Dansky L. Maternal epilepsy and congenital malformations:
correlation with maternal plasma anticonvulsant levels during pregnancy.
In: Janz D, editor. Epilepsy, pregnancy and the child. New York:
Raven Press; 1982. p 251–8.
83. Nakane Y, Okuma T, Takahashi R, Sato Y, Wada T,
Sato T,and others: Multi-institutional study on the teratogenicity
and fetal toxicity of antiepileptic drugs: a report of a collaborative
study group in Japan. Epilepsia 1980;21:663–80.
84. Lindhout D, Omtzigt JG. Teratogenic effects of
antiepileptic drugs: implications for the management of epilepsy
in women of childbearing age. Epilepsia 1994;35 (Suppl 4):S19–S28.
85. Delgado-Escueta AV, Janz D. Consensus guidelines:
preconception counseling, management, and care of the pregnant woman
with epilepsy. Neurology 1992;42 (Suppl 5):149–60.
86. Rosa FW: Spina bifida in infants of women treated
with carbamazepine during pregnancy. N Engl J Med 1991;324:674–7.
87. Jones KL, Lacro RV, Johnson KA, Adams J. Pattern
of malformation in the children of women treated with carbamazepine
during pregnancy. N Engl J Med. 1989;320:1661–6.
88. Devinsky O, Cramer J. Safety and efficacy of standard
and new antiepileptic drugs. Neurology 2000;55 (Suppl 3):S5–S10.
89. Robert E, Guibaud P. Maternal valproic acid and
congenital neural tube defects. Lancet 1982;2:937.
90. Omtzigt JG, Los FJ, Grobbee DE, Pijpers L, Jahode
MG, Brandenburg H, and others. The risk of spina bifida aperta after
first-trimester exposure to valproate in a prenatal cohort. Neurology
1992;42 (Suppl 5):119–25.
91. Vanverloop D, Schnell RR, Harvey EA, Holmes LB.
The effects of prenatal exposure to phenytoin and other anticonvulsants
on intellectual function at 4 to 8 years of age. Neurotoxicology
and Teratology 1992;14:329–35.
92. Scolnik D, Nulman I, Rovet J, Gladstone D, Czuchta
D, Gardner HA, and others. Neurodevelopment of children exposed
in utero to phenytoin and carbamazepine monotherapy. JAMA 1994;271:767–70.
93. Adams J, Harvey EA, Holmes LB. Cognitive deficits
following gestational monotherapy with phenobarbital and carbamazepine.
Neurotoxicol Teratol 2000;22:453–67.
94. Reinisch JM, Sanders SA, Mortensen EL, Rubin DB.
In utero exposure to phenobarbital and intelligence deficits in
adult men. JAMA 1995;724:1518–25.
95. Ernst CL, Goldberg JF. The reproductive safety
profile of mood stabilizers, atypical antipsychotics, and broad-spectrum
psychotropics. J Clin Psychiatry 2002;63 (Suppl 4):42–55.
96. Lamotrigine Pregnancy Registry. Interim report,
September 1992 through March 2001. Research Triangle (NC): GlaxoSmith
Kline Corporation; 2002.
97. Morrow JI, Craig JJ, Russell AJC. Epilepsy and
pregnancy: A prospective register in the United Kingdom. J Neurol
Sci 2001;187 (Suppl 1):S299.
98. Gregoire A, Pearson S. Risk of pregnancy when changing
to atypical antipsychotics. Br J Psychiatry 2002;180:83–4.
99. Kopelman AE, McCullar FW, Heggeness L. Limb malformations
following maternal use of haloperidol. JAMA 1975;231:62–4.
100. Hanson JW, Oakley GP Jr. Haloperidol and limb
deformity [letter]. JAMA 1975;231:26.
101. Slone D, Siskind V, Heinonen OP, Monson RR, Kaufman
DW, Shapiro S. Antenatal exposure to the phenothiazines in relation
to congenital malformations, perinatal mortality rate, birth weight,
and intelligence quotient score. Am J Obstet Gynecol 1977;128:486–8.
102. Milkovich L, van den Berg BJ. An evaluation of
the teratogenicity of certain antinauseant drugs. Am gentlemen Obstet
Gynecol 1976;125:224–8.
103. Barnas C, Bergant A, Hummer M, Saria A, Fleischhacker
WW. Clozapine concentrations in maternal and fetal plasma, amniotic
fluid, and breast milk [letter]. Am J Psychiatry 1994;151:945.
104. Waldman MD, Safferman AZ. Pregnancy and clozapine.
Am J Psychiatry 1993;150:168–9.
105. Stoner SC, Sommi RW Jr, Marken PA. Clozapine use
in two full-term pregnancies [letter]. J Clin Psychiatry 1997;58:364–5.
106. Dickson RA, Hogg L. Pregnancy of a patient treated
with clozapine. Psychiatr Serv 1998;49:1081–3.
107. Registry of Clozaril® babies. East Hanover
(NJ): Novartis Corp; 2002.
108. Goldstein DJ, Corbin LA, Fung MC. Olanzapine-exposed
pregnancies and lactation: early experience. J Clin Psychopharmacol
2000;20:399–403.
109. Hill RM, Desmond MM, Kay JL: Extrapyramidal dysfunction
in an infant of a schizophrenic mother. J Pediatr 1966;69:589–95.
110. Auerbach JG, Hans SL, Marcus J, Maeir S. Maternal
psychotropic medication and neonatal behavior. Neurotoxicol Teratol
1992;14:399–406.
111. Desmond MM, Rudolph AJ, Hill RM. Behavioral alterations
in infants born to mothers on psychoactive medication during pregnancy.
In: Farrell G, editor. Congenital mental retardation. Austin: University
of Texas; 1967.
112. Nonacs R, Viguera A, Cohen L. Risks of postpartum
relapse in pregnant women with bipolar disorder. In: Syllabus and
proceedings summary of the 151st Annual Meeting of the American
Psychiatric Association; May 17-22, 1997; Toronto (ON). Washington
(DC): APA; 1998.
113. Ferrill MJ, Kehoe WA, Jacisin JJ. ECT during pregnancy:
physiological and pharmacologic considerations. Convul Ther 1992;8:186–200.
114. Miller LJ. Use of electroconvulsive therapy during
pregnancy. Hospital and Community Psychiatry 1994;45:444–50.
115. Chaudron LH, Jefferson J. Mood stabilizers during
breastfeedig: a review. J Clin Psychiatry 2000;61:79–90.
116. Burt VK, Suri R, Altshuler L, Stowe Z, Hendrick
V, Muntean E. The use of psychotropic medications during breastfeeding.
Am J Psychiatry 2001;158:1001–9.
--------------------------------------------------------------------------------
Manuscript received and accepted April 2002.
1 Associate Director, Perinatal and Reproductive Psychiatry Program,
Massachusetts General Hospital; Instructor in Psychiatry, Harvard
Medical School, Boston, Massachusetts.
2 Director, Perinatal and Reproductive Psychiatry Program, Massachusetts
General Hospital; Associate Professor of Psychiatry, Harvard Medical
School, Boston, Massachusetts.
3 Director, Bipolar and Psychotic Disorders and Psychopharmacology
Programs, Laboratories for Psychiatric Research, and International
Consortium for Bipolar Disorder Research, McLean Division of Massachusetts
General Hospital; Professor of Psychiatry and, Neuroscience, Harvard
Medical School, Boston, Massachusetts.
4 Instructor in Psychiatry, Harvard Medical School, Massachusetts
General Hospital, Boston, Massachusetts.
Address for correspondence: Dr AC Viguera, Perinatal and Reproductive
Psychiatry Program, Department of Psychiatry, WACC 812, Massachusetts
General Hospital, Boston, MA 02114
e-mail: aviguera@partners.org
|
